

Ayrton Drug Manufacturing Limited

Un-audited Profit and Loss Account For the three months ended 31st March 2009

	Notes	2009 GH¢	2008 GH¢ Restated
Sale of goods		3,222,221	2,416,675
<hr/>			
Revenue		3,222,221	2,416,675
Cost of Sales	2.1	(1,789,788)	(1,408,903)
<hr/>			
Gross Profit		1,432,433	1,007,772
Other Income	2.12	3,373	13,693
Selling and distribution expenses	2.2	(193,785)	(125,575)
Administration and general expenses	2.3	(426,563)	(275,275)
<hr/>			
Operating Profit		815,458	620,615
Finance cost	2.4	(833)	(1,012)
Finance income		9,311	10,858
<hr/>			
Profit before taxation		823,936	630,461
Income tax expense	2.5	178,535	(137,438)
<hr/>			
Profit for the period		645,401	493,023
<hr/> <hr/>			
Earnings per share		0.0030	0.0023

Ayrton Drug Manufacturing Limited

Un-audited Balance Sheet

As at 31st March 2009

	Note	2009 GH¢	2008 GH¢ Restated
Assets			
Non current assets			
Property, plant and equipment	2.6	2,715,410	2,738,922
Intangible assets	2.7	266,292	0

		2,981,702	2,738,922

Current Assets			
Inventories	2.8	5,957,558	3,391,274
Trade and other receivables	2.9	2,316,080	2,592,436
Other current financial assets		0	300,000
Cash and bank balances	2.1	733,901	846,503

		9,007,539	7,130,213

			-
Total assets		11,989,241	9,869,135

Equity and liabilities			
Equity attributable to equity holders			
Stated capital	2.13	4,475,000	4,475,000
Other capital reserves		495,294	495,294
Income surplus		4,999,067	3,325,678

Total equity		9,969,361	8,295,972

Current liabilities			
Trade and other payables	2.11	1,837,524	1,392,005
Income tax payable	2.5	182,356	181,158

Total liabilities		2,019,880	1,573,163

Total equity and liabilities		11,989,241	9,869,135

The financial statement do not contain untrue statements, misleading facts or omits material facts to the best of our knowledge.

Samuel Adjepong
(Managing Director)

Belinda Opoku (Mrs)
(Director)

AYRTON DRUG MANUFACTURING LIMITED

Statement of Changes in Equity

For the three months ended 31st March 2009

	Issued Capital GH¢	Income surplus GH¢	Other reserves GH¢	Total GH¢
Balance at 1 January	4,475,000	4,353,666	495,295	9,323,961
Total recognised income and expense	0	645,401	0	645,401
Balance at 31st March	4,475,000	4,999,067	495,295	9,969,362

	Mar-09 Issued Capital GH¢	Income surplus GH¢	Other reserves GH¢	Total GH¢
Balance 1st January	4,475,000	2,832,655	495,294	7,802,949
Total recognised income and expense	0	493,023		493,023
Balance at 31st March	4,475,000	3,325,678	495,294	8,295,972

Ayrton Drug Manufacturing Limited

Un-audited Cash Flow Statement

For the three months ended 31st March 2009

	2009	2008
	GH¢	GH¢
		Restated
Operating activities		
Profit before tax	823,936	630,461
Adjustment		
Adjustment to reconcile profit before tax to net cash flows		
Depreciation charges	111,068	105,349
Amortisation	8,042	0
Working capital adjustments:		
Increase in inventory	(1,434,020)	(1,045,014)
Increase/decrease in trade and other receivables	189	(231,715)
Increas/decreasee in trade and other payables	816,539	558,399
Income tax paid	(100,079)	(95,635)
	-----	-----
Net cash flow from operating activities	225,675	225,675
	-----	-----
Investing activities		
Purchase of property, plant and equipment	(62,818)	(260,172)
	-----	-----
Financing activities		
Dividends paid to equity holders	0	0
	-----	-----
Net (decrease)/increase in cash and cash equivalent	162,857	(338,327)
Cash and csh equivalent at 1 January	571,044	1,184,830
	-----	-----
Cash and cash equivalent at 31 March	733,901	846,503